Bivalirudin (bivalirudin)
Thrombin Inhibitors (Non-Heparinoid) Intravenous Vial (Ea); Intravenous Vial (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Bivalirudin trifluoroacetate, a synthetic analog of hirudin that acts as a direct thrombin inhibitor, is an anticoagulant.
Bivalirudin, a synthetic 20-amino acid peptide analog of naturally occurring hirudin, is an anticoagulant. Hirudin is the polypeptide that is responsible for the anticoagulant properties of the saliva of the medicinal leech (Hirudo medicinalis).
Bivalirudin is a specific and reversible direct thrombin inhibitor that binds to the catalytic site and the anion-binding exosite of circulating and clot-bound thrombin. Inhibition of thrombin prevents various steps in the coagulation process (e.g., activation of factors V, VIII, and XIII; conversion of fibrinogen to fibrin; platelet activation and aggregation). These effects of bivalirudin are reversed as thrombin slowly cleaves the bivalirudin-Arg3-Pro4 bond, resulting in recovery of thrombin active site function.
The onset of anticoagulant effect is immediate following direct IV injection of bivalirudin. Bivalirudin therapy prolongs several coagulation assays, including the activated clotting time (ACT), activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT). Coagulation times return to the normal range approximately 1-2 hours after discontinuance of the drug.
Generic name: bivalirudin
Drug class: Thrombin Inhibitors (Non-Heparinoid)
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Bivalirudin
Indications
The following indications are listed for Bivalirudin:
- Percutaneous Coronary Intervention Adjunct For Thrombosis Prevention
- Thrombosis Prevention During Percutaneous Coronary Intervention In Heparin-Induced Thrombocytopenia
- Thrombosis With Heparin-Induced Thrombocytopenia During Percutaneous Coronary Intervention
Also known as: Heparin-Induced Thrombotic Thrombocytopenia During Percutaneous Coronary Intervention, Thrombosis In Heparin-Induced Thrombopenia During Percutaneous Coronary Intervention, Thrombosis Prophylaxis During Percutaneous Coronary Intervention In Heparin-Induced Thrombocytopenia, White Clot Syndrome During Percutaneous Coronary Intervention, White-Clot Syndrome During Percutaneous Coronary Intervention.
Dosing
Dosage of bivalirudin trifluoroacetate is expressed in terms of bivalirudin.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Anticoagulant;Antiplatelet;Thrombolytic/Alipogene Tiparvovec
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Alipogene tiparvovec is given as a one-time series of intramuscular (IM)injections. Depending upon patient weight 27 to 60 injections are given, each at a different site.
CLINICAL EFFECTS: Concurrent use of anticoagulant, antiplatelet, or thrombolytic agents increase bleeding risk at IM injection sites.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Antiplatelet or other anticoagulant agents must not be taken for at least one week prior to alipogene tiparvovec therapy. Assure that abnormal bleeding parameters have been corrected prior to administration. Antiplatelet or anticoagulant therapy may be resumed one day after alipogene tiparvovec administration. If concurrent therapy is deemed medically necessary, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Alipogene tiparvovec is given as a one-time series of intramuscular (IM)injections for the treatment of familial lipoprotein lipase deficiency. Depending upon patient weight 27 to 60 injections are given, each at a different site. Concurrent use of anticoagulant, antiplatelet, or thrombolytic agents increase bleeding risk at IM injection sites.
Anticoagulants/Hemin
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Mild, transient anticoagulant effects has been reported with the use of hemin.(1)
CLINICAL EFFECTS: Concurrent use of hemin with anticoagulants may increase the risk of bleeding.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The manufacturer of hemin states concurrent use with anticoagulant therapy should be avoided.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Mild, transient anticoagulant effects have been reported during clinical studies with hemin.(1)
Anticoagulants/Iv And Im Diclofenac
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The exact mechanism is unknown. Diclofenac impairs platelet function and may prolong bleeding time.(1-2) Diclofenac also has the potential to produce gastrointestinal ulceration and bleeding.(1-2)
CLINICAL EFFECTS: Concurrent use of diclofenac and anticoagulants may increase the risk of bleeding complications.(1-2)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The Middle East manufacturer of injectable diclofenac states the use of intravenous diclofenac in patients on anticoagulants, including low-dose heparin, is contraindicated.(1) The UK manufacturer of injectable diclofenac states the use of intramuscular and intravenous diclofenac in patients on anticoagulants, including low-dose heparin, is contraindicated.(2) The Israeli and Swedish manufacturers of injectable diclofenac advise caution and close monitoring during concurrent use of anticoagulants.(3-4) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there are reports of an increased risk of hemorrhage in patients receiving diclofenac and anticoagulants concomitantly.(2) The Middle East and UK manufacturers of diclofenac state the use of intravenous and intramuscular diclofenac in patients on anticoagulants, including low-dose heparin, is contraindicated.(1-2)
Anticoagulants; Thrombolytics/Apixaban
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Additive effects on hemostasis.
CLINICAL EFFECTS: Concurrent use of apixaban with anticoagulants or thrombolytics may increase the risk of bleeding.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The long-term use of concurrent therapy with direct oral anticoagulants (DOACs) and other anticoagulants is generally considered contraindicated. However, overlap may be necessary when switching therapy from one agent to another in order to prevent thrombotic events. Manufacturer recommendations concerning overlap (if any) and timing of discontinuation versus initiation vary depending upon which agent is being discontinued and initiated. Refer to current prescribing information for both agents for additional details. Specific recommendations for converting between anticoagulants: - When converting between apixaban and anticoagulants other than warfarin, discontinue the current anticoagulant and begin the new one when next dose is due. - When converting from warfarin to apixaban, discontinue warfarin and begin apixaban when the international normalized ratio (INR) is below 2.0. - Apixaban affects INR. Therefore concurrent administration with warfarin when converting from apixaban to warfarin is not useful in determining target warfarin dose. If continuous anticoagulation is warranted, discontinue apixaban and begin both warfarin and a parenteral anticoagulant when next dose of apixaban is due. Once INR is within range, discontinue the parenteral anticoagulant. The use of concurrent therapy with Direct Oral Anticoagulants (DOACs) and thrombolytics is generally considered contraindicated. The manufacturer of alteplase states that the use of alteplase for an indication of acute ischemic stroke is contraindicated in patients receiving anticoagulants. Concurrent use of alteplase and anticoagulants is dependent on the therapeutic indication. In Acute Ischemic Stroke: - Clinical practice guidelines for acute ischemic stroke state the use of thrombolytic therapy for an indication of acute ischemic stroke is contraindicated in patients who have received thrombin inhibitors or factor Xa inhibitors in the previous 48 hours (in normal renal function) and have abnormal laboratory tests such as activated partial thromboplastin time (aPTT), INR, platelet count, ecarin clotting time (ECT), thrombin time, or direct factor Xa assays at presentation. In Acute Myocardial Infarction: - Patients who are receiving thrombolytics for an indication of acute myocardial infarction should be carefully monitored for signs of bleeding, especially at arterial puncture sites, if apixaban is used concurrently. - The use of thrombolytics in patients with acute myocardial infarction should follow standard management of myocardial infarction, including minimizing arterial and venous puncture; avoid noncompressible arterial puncture; and minimize internal jugular and subclavian venous punctures to decrease bleeding from the noncompressible sites. For all indications: - In the event of serious bleeding, anticoagulants should be discontinued immediately. - If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. - When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. - Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Limited overlap of DOACs with other anticoagulants may be required when initiating or discontinuing DOACs in order to prevent thrombotic events. However, long-term concomitant treatment is not recommended because of increased risk of bleeding. Patients who are receiving thrombolytics should be carefully monitored for signs of bleeding if anticoagulants are being used concurrently or have recently been used.
Anticoagulants; Thrombolytics/Betrixaban
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Additive effects on hemostasis.
CLINICAL EFFECTS: Concurrent use of betrixaban with anticoagulants or thrombolytics may increase the risk of bleeding.
PREDISPOSING FACTORS: Patients with severe renal impairment (CrCl< 30 ml/min) or taking a concomitant P-gp inhibitor.
PATIENT MANAGEMENT: The long-term use of concurrent therapy with direct oral anticoagulants (DOACs) and other anticoagulants is generally considered contraindicated. However, overlap may be necessary when switching therapy from one agent to another in order to prevent thrombotic events. Manufacturer recommendations concerning overlap (if any) and timing of discontinuation versus initiation vary depending upon which agent is being discontinued and initiated. Refer to current prescribing information for both agents for additional details. The use of concurrent therapy with Direct Oral Anticoagulants (DOACs) and thrombolytics is generally considered contraindicated. The manufacturer of alteplase states that the use of alteplase for an indication of acute ischemic stroke is contraindicated in patients receiving anticoagulants. Concurrent use of alteplase and anticoagulants is dependent on the therapeutic indication. In Acute Ischemic Stroke: - Clinical practice guidelines for acute ischemic stroke state the use of thrombolytic therapy for an indication of acute ischemic stroke is contraindicated in patients who have received thrombin inhibitors or factor Xa inhibitors in the previous 48 hours (in normal renal function) and have abnormal laboratory tests such as activated partial thromboplastin time (aPTT), INR, platelet count, ecarin clotting time (ECT), thrombin time, or direct factor Xa assays at presentation. In Acute Myocardial Infarction: - Patients who are receiving thrombolytics for an indication of acute myocardial infarction should be carefully monitored for signs of bleeding, especially at arterial puncture sites, if betrixaban is used concurrently. - The use of thrombolytics in patients with acute myocardial infarction should follow standard management of myocardial infarction, including minimizing arterial and venous puncture; avoid noncompressible arterial puncture; and minimize internal jugular and subclavian venous punctures to decrease bleeding from the noncompressible sites. For all indications: - In the event of serious bleeding, anticoagulants should be discontinued immediately. - If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. - When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. - Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Patients who are receiving thrombolytics should be carefully monitored for signs of bleeding if anticoagulants are being used concurrently or have recently been used.
Anticoagulants; Thrombolytics/Dabigatran
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Dabigatran is a direct thrombin inhibitor. When taken with agents that affect clotting factors, increased bleeding episodes can occur.
CLINICAL EFFECTS: Concurrent use of dabigatran with anticoagulants or thrombolytics may result in additive or synergistic effects resulting in unwanted bleeding episodes.
PREDISPOSING FACTORS: Factors associated with an increase risk for bleeding include renal impairment, concomitant use of P-glycoprotein inhibitors, patient age >74 years, coexisting conditions (e.g. recent trauma) or use of drugs (e.g. NSAIDs) associated with bleeding risk, and patient weight <50 kg.(1-3) The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The long-term use of concurrent therapy with direct oral anticoagulants (DOACs) and other anticoagulants is generally considered contraindicated. However, overlap may be necessary when switching therapy from one agent to another in order to prevent thrombotic events. Manufacturer recommendations concerning overlap (if any) and timing of discontinuation versus initiation vary depending upon which agent is being discontinued and initiated. Refer to current prescribing information for both agents for additional details. Specific recommendations for converting between anticoagulants: - When converting from parenteral anticoagulants to dabigatran, administer dabigatran 0-2 hours before the next dose of the parenteral drug is due. - When converting from dabigatran to a parenteral anticoagulant in adults, begin parenteral anticoagulant: --12 hours after last dose of dabigatran in patients with CrCl greater than or equal to 30 ml/min, --24 hours after last dose of dabigatran in patients with CrCl less than 30 ml/min. - When converting from dabigatran to a parenteral anticoagulant in pedatrics, begin the parenteral anticoagulant 12 hours after the last dose of dabigatran. - When converting from warfarin to dabigatran, discontinue warfarin and begin dabigatran when the patient's INR is below 2.0. - When converting from dabigatran to warfarin in adults, start warfarin: --3 days before discontinuing dabigatran in patients with CrCl greater than 50 ml/min, --2 days before discontinuing dabigatran in patients with CrCl of 30 ml/min to 50 ml/min, --1 day before discontinuing dabigatran in patients with CrCl of 15 ml/min to 30 ml/min. --There is no recommendation available for converting dabigatran to warfarin in patients with CrCl less than 15 ml/min. - When converting from dabigatran to warfarin in pediatrics, start warfarin: --3 days before discontinuing dabigatran in patient with eGFR >= 50 ml/min/1.73 m2. --There is no data on using dabigatran in pediatric patients with eGFR < 50 ml/min/1.73 m2. - Dabigatran affects INR. Therefore the INR will better reflect warfarin's effect only after stopping dabigatran for at least 2 days. The use of concurrent therapy with Direct Oral Anticoagulants (DOACs) and thrombolytics is generally considered contraindicated. The manufacturer of alteplase states that the use of alteplase for an indication of acute ischemic stroke is contraindicated in patients receiving anticoagulants. Concurrent use of alteplase and anticoagulants is dependent on the therapeutic indication. In Acute Ischemic Stroke: - Clinical practice guidelines for acute ischemic stroke state the use of thrombolytic therapy for an indication of acute ischemic stroke is contraindicated in patients who have received thrombin inhibitors or factor Xa inhibitors in the previous 48 hours (in normal renal function) and have abnormal laboratory tests such as activated partial thromboplastin time (aPTT), INR, platelet count, ecarin clotting time (ECT), thrombin time, or direct factor Xa assays at presentation. In Acute Myocardial Infarction: - Patients who are receiving thrombolytics for an indication of acute myocardial infarction should be carefully monitored for signs of bleeding, especially at arterial puncture sites, if dabigatran is used concurrently. - The use of thrombolytics in patients with acute myocardial infarction should follow standard management of myocardial infarction, including minimizing arterial and venous puncture; avoid noncompressible arterial puncture; and minimize internal jugular and subclavian venous punctures to decrease bleeding from the noncompressible sites. For all indications: - In the event of serious bleeding, anticoagulants should be discontinued immediately. - If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. - When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. - Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Patients who are receiving thrombolytics should be carefully monitored for signs of bleeding if anticoagulants are being used concurrently or have recently been used.
Anticoagulants; Thrombolytics/Edoxaban
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Additive effects on hemostasis.
CLINICAL EFFECTS: Concurrent use of edoxaban with anticoagulants or thrombolytics may increase the risk of bleeding.
PREDISPOSING FACTORS: Bleeding risk may be increased in patients with renal impairment and in patients > 75 years of age. Use of multiple agents which affect hemostasis increases the risk for bleeding.
PATIENT MANAGEMENT: The long-term use of concurrent therapy with direct oral anticoagulants (DOACs) and other anticoagulants is generally considered contraindicated. However, overlap may be necessary when switching therapy from one agent to another in order to prevent thrombotic events. Manufacturer recommendations concerning overlap (if any) and timing of discontinuation versus initiation vary depending upon which agent is being discontinued and initiated. Refer to current prescribing information for both agents for additional details. Specific recommendations for converting between anticoagulants: - When converting from other (non-vitamin K antagonist) oral anticoagulants to edoxaban, discontinue current oral anticoagulant and start edoxaban at the time of the next scheduled dose of the old oral anticoagulant. - When converting from a low molecular weight heparin (LMWH) to edoxaban, start edoxaban at the time of the next scheduled administration of LMWH. - When converting from unfractionated heparin to edoxaban, discontinue the infusion and start edoxaban 4 hours later. - When converting from edoxaban to another DOAC, discontinue edoxaban and begin the new oral anticoagulant at the time of the next scheduled dose of edoxaban. - When converting from edoxaban to parenteral anticoagulation, start the parenteral anticoagulant at the time of the next dose of edoxaban. - When converting from warfarin to edoxaban, discontinue warfarin and start edoxaban when the INR is < or = to 2.5. - When converting from edoxaban to warfarin, for patients taking 60 mg of edoxaban, reduce the dose to 30 mg and begin warfarin concomitantly. For patients receiving 30 mg of edoxaban, reduce the dose to 15 mg and begin warfarin concomitantly. INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the effects of edoxaban on INR measurement. Once a stable INR = or > 2.0 is achieved, edoxaban should be discontinued and the warfarin continued. - A second edoxaban to warfarin conversion option: Discontinue edoxaban and administer a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Once a stable INR = or > 2.0 is achieved, the parenteral anticoagulant should be discontinued and the warfarin continued. The use of concurrent therapy with Direct Oral Anticoagulants (DOACs) and thrombolytics is generally considered contraindicated. The manufacturer of alteplase states that the use of alteplase for an indication of acute ischemic stroke is contraindicated in patients receiving anticoagulants. Concurrent use of alteplase and anticoagulants is dependent on the therapeutic indication. In Acute Ischemic Stroke: - Clinical practice guidelines for acute ischemic stroke state the use of thrombolytic therapy for an indication of acute ischemic stroke is contraindicated in patients who have received thrombin inhibitors or factor Xa inhibitors in the previous 48 hours (in normal renal function) and have abnormal laboratory tests such as activated partial thromboplastin time (aPTT), INR, platelet count, ecarin clotting time (ECT), thrombin time, or direct factor Xa assays at presentation. In Acute Myocardial Infarction: - Patients who are receiving thrombolytics for an indication of acute myocardial infarction should be carefully monitored for signs of bleeding, especially at arterial puncture sites, if edoxaban is used concurrently. - The use of thrombolytics in patients with acute myocardial infarction should follow standard management of myocardial infarction, including minimizing arterial and venous puncture; avoid noncompressible arterial puncture; and minimize internal jugular and subclavian venous punctures to decrease bleeding from the noncompressible sites. For all indications: - In the event of serious bleeding, anticoagulants should be discontinued immediately. - If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. - When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. - Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Limited overlap of DOACs with other anticoagulants may be required when initiating or discontinuing DOACs in order to prevent thrombotic events. However, long-term concomitant treatment is not recommended because of increased risk of bleeding. Patients who are receiving thrombolytics should be carefully monitored for signs of bleeding if anticoagulants are being used concurrently or have recently been used.
Anticoagulants; Thrombolytics/Rivaroxaban
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Additive effects on hemostasis.
CLINICAL EFFECTS: Concurrent use of rivaroxaban with anticoagulants or thrombolytics may increase the risk of bleeding.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The long-term use of concurrent therapy with direct oral anticoagulants (DOACs) and other anticoagulants is generally considered contraindicated. However, overlap may be necessary when switching therapy from one agent to another in order to prevent thrombotic events. Manufacturer recommendations concerning overlap (if any) and timing of discontinuation versus initiation vary depending upon which agent is being discontinued and initiated. Refer to current prescribing information for both agents for additional details. Specific recommendations for converting between anticoagulants: - When converting from rivaroxaban to anticoagulants other than warfarin and switching to an anticoagulant with rapid onset, discontinue rivaroxaban and begin new anticoagulant when next dose of rivaroxaban is due. - When converting from anticoagulants other than warfarin to rivaroxaban, discontinue current anticoagulant and begin rivaroxaban between 0-2 hours before next evening dose of the drug is due. For patients receiving continuous infusion of unfractionated heparin, simultaneously stop the infusion and administer rivaroxaban. - When converting from warfarin to rivaroxaban, discontinue warfarin and begin rivaroxaban once international normalized ratio (INR) is below 3.0 in adults and below 2.5 in pediatric patients. - When converting from rivaroxaban to warfarin in adults, rivaroxaban affects INR. Therefore concurrent administration with warfarin is not useful in determining target warfarin dose. If continuous anticoagulation is warranted, discontinue rivaroxaban and begin both warfarin and a parenteral anticoagulant when the next dose of rivaroxaban is due. Once INR is within range, discontinue the parenteral anticoagulant. - When converting from rivaroxaban to warfarin in pediatrics, continue rivaroxaban for at least 2 days after the first dose of warfarin. After two days, INR should be measured just prior to the next scheduled dose of rivaroxaban. Once a stable INR = or > 2.0 is achieved, rivaroxaban should be discontinued and warfarin continued. The use of concurrent therapy with Direct Oral Anticoagulants (DOACs) and thrombolytics is generally considered contraindicated. The manufacturer of alteplase states that the use of alteplase for an indication of acute ischemic stroke is contraindicated in patients receiving anticoagulants. Concurrent use of alteplase and anticoagulants is dependent on the therapeutic indication. In Acute Ischemic Stroke: - Clinical practice guidelines for acute ischemic stroke state the use of thrombolytic therapy for an indication of acute ischemic stroke is contraindicated in patients who have received thrombin inhibitors or factor Xa inhibitors in the previous 48 hours (in normal renal function) and have abnormal laboratory tests such as activated partial thromboplastin time (aPTT), INR, platelet count, ecarin clotting time (ECT), thrombin time, or direct factor Xa assays at presentation. In Acute Myocardial Infarction: - Patients who are receiving thrombolytics for an indication of acute myocardial infarction should be carefully monitored for signs of bleeding, especially at arterial puncture sites, if rivaroxaban is used concurrently. - The use of thrombolytics in patients with acute myocardial infarction should follow standard management of myocardial infarction, including minimizing arterial and venous puncture; avoid noncompressible arterial puncture; and minimize internal jugular and subclavian venous punctures to decrease bleeding from the noncompressible sites. For all indications: - In the event of serious bleeding, anticoagulants should be discontinued immediately. - If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. - When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. - Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Patients who are receiving thrombolytics should be carefully monitored for signs of bleeding if anticoagulants are being used concurrently or have recently been used.
Bivalirudin; Desirudin/Gpis;Heparin;Thrombolytics;Warfarin
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Concurrent use may result in additive effects on hemostasis.(1,2)
CLINICAL EFFECTS: Concurrent use of bivalirudin with GPIs, heparin, or warfarin may increase the risk of bleeding.(1,2)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Concurrent use of bivalirudin and GPIs, heparin, or warfarin should be avoided.(1) Discontinue agents that may increase the risk of hemorrhage prior to initiation of desirudin.(2) The Australian manufacturer of bivalirudin states patients can be started on bivalirudin 30 minutes after discontinuation of unfractionated heparin or 8 hours after discontinuation of low molecular weight heparin.(3) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: In clinical trials, concurrent use of bivalirudin with GPIs, heparin, or warfarin was associated with increased risks of major bleeding events compared to patients not receiving concurrent therapy.(1) Concurrent administration of warfarin did not affect the pharmacokinetics of desirudin; however, greater inhibition of hemostasis was observed as seen by aPPT, PT and INR measurements.(2)
Selected Anticoagulants; Thrombolytics/Defibrotide
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Concurrent use may result in additive effects on hemostasis.(1)
CLINICAL EFFECTS: Concurrent use of defibrotide with anticoagulants or thrombolytics may increase the risk of bleeding.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The US manufacturer of defibrotide states that concomitant use with systemic anticoagulant or antithrombotic therapy is contraindicated.(1) In patients who have received prior anticoagulant or thrombolytic therapy, consider delaying the start of defibrotide until the effects of the anticoagulant have abated.(1) If concurrent therapy is deemed medically necessary, closely monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding; gingival bleeding; nosebleeds; unusual bruising; orange/red urine or dark/black stools; new onset of headache, confusion, slurred speech, or vision; acute abdominal pain; or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: In pivotal clinical trials, 176 patients received defibrotide; the use of anticoagulants or thrombolytics was not allowed. Bleeding events not attributed to underlying disease were as follows: epistaxis (14%), pulmonary alveolar hemorrhage (9%), gastrointestinal hemorrhage (9%), pulmonary hemorrhage (9%), intracranial hemorrhage (3%), cerebral hemorrhage (2%).
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Anticoagulants/Donanemab
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Microhemorrhage has been reported with the use of donanemab. Radiographic changes on brain MRI have been noted as amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H) which included microhemorrhage. In addition, intracerebral hemorrhages (ICH) greater than 1 cm in diameter have occurred in patients treated with donanemab.(1)
CLINICAL EFFECTS: Concurrent use of donanemab with anticoagulants agents may increase the risk of hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Donanemab should be used with extreme caution in patients treated with anticoagulants. Evaluate the risks and benefits of concurrent use of donanemab with anticoagulants.(1) The manufacturer of donanemab recommends testing for AP0E4 status prior to initiation of treatment.(1) Use of anticoagulant agents in patients who are homozygous for the APOE4 gene, may have an increased risk of ARIA with donanemab therapy.(1-3) If concurrent therapy is warranted, patients receiving concurrent therapy with donanemab and anticoagulants should be closely monitored for signs and symptoms of bleeding and changes in platelet count or International Normalized Ratio (INR).(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of microhemorrhage, including headache, nausea/vomiting, confusion, dizziness, visual disturbance, gait difficulties, and loss of coordination. General signs of blood loss include decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as confusion, headache, dizziness, nausea, visual changes, unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: In a double-blind, placebo-controlled clinical study of 1736 participants randomized to receive donanemab (n = 860) or placebo (n = 876), donanemab was observed to increase amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H), including microhemorrhage and intracerebral hemorrhage (ICH). Radiographic changes were classified as mild (<=4 new incidences), moderate (5 to 9 new incidences), or severe (10 or more new incidences). The maximum severity of ARIA-H microhemorrhage was observed as mild in 17% (143/853), moderate in 4% (34/853), and severe in 5% (40/853) of patients taking donanemab.(1) Baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed. The majority of exposures to antithrombotic medications were to aspirin. The incidence of ARIA-H was 30% (106/349) in patients taking donanemab with a concomitant antithrombotic medication within 30 days compared to 29% (148/504) who did not receive an antithrombotic within 30 days of an ARIA-H event.(1) The incidence of ICH greater than 1 cm in diameter was 0.6% (2/349 patients) in patients taking donanemab with a concomitant antithrombotic medication compared to 0.4% (2/504) in those who did not receive an antithrombotic. One fatal ICH occurred in a patient taking donanemab in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.(1) The manufacturer of donanemab states the number of events and the limited exposure to non-aspirin antithrombotic medications limit definitive conclusions about the risk of ARIA or ICH in patients taking antithrombotic medications concurrently with donanemab. If concurrent therapy is warranted, patients should be closely monitored for signs and symptoms of bleeding and changes in platelet count or INR.(1)
Anticoagulants/Ketorolac
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The exact mechanism is unknown. Ketorolac impairs platelet function and may prolong bleeding time.(1) Ketorolac also has the potential to produce gastrointestinal ulceration and bleeding.(1-3)
CLINICAL EFFECTS: Concurrent use of ketorolac and anticoagulants may increase the risk of bleeding complications.(1-3)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The Australian(1) and UK(2) manufacturers of ketorolac state that the use of ketorolac in patients on anticoagulants, including low-dose heparin,(2) is contraindicated. The US manufacturer of ketorolac states that concurrent therapy with anticoagulants should be undertaken with extreme caution after carefully weighing the benefits of concurrent therapy against the risks and that patients receiving concurrent therapy should be closely monitored.(3) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Ketorolac has been shown to inhibit platelet aggregation and may prolong bleeding times. Ketorolac-induced inhibition of platelet function disappears within 24 to 48 hours after ketorolac discontinuation. Ketorolac does not affect platelet count, prothrombin time (PT), or partial thromboplastin time (PTT).(1) Ketorolac has been shown in vitro to only slightly reduce warfarin protein binding (from 99.5% to 99.3%.(3) In a study in 12 subjects, ketorolac had no effects on the pharmacokinetics or pharmacodynamics of a single dose of warfarin (25 mg). In another study in 11 subjects, ketorolac increased the mean template bleeding time for 2 doses of heparin from 6.0 to 6.4 minutes.(3)
Anticoagulants/Lecanemab
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Microhemorrhage has been reported with the use of lecanemab. Radiographic changes on brain MRI have been noted as amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H) which included microhemorrhage. In addition, intracerebral hemorrhages (ICH) greater than 1 cm in diameter have occurred in patients treated with lecanemab.(1)
CLINICAL EFFECTS: Concurrent use of lecanemab with anticoagulants agents may increase the risk of hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The US manufacturer of lecanemab advises extreme caution in patients treated with anticoagulants. Evaluate the risks and benefits of concurrent use of lecanemab with anticoagulants.(1) Appropriate use recommendations for lecanemab state patients on anticoagulants should not receive lecanemab.(2) The UK manufacturer of lecanemab contraindicates initiation of lecanemab in patients receiving ongoing anticoagulant therapy. If anticoagulation is necessary, then lecanemab should be paused. Lecanemab can be reinstated if anticoagulation is no longer medically indicated.(3) If concurrent therapy is warranted, patients should be closely monitored for signs and symptoms of microhemorrhage, including headache, nausea/vomiting, confusion, dizziness, visual disturbance, gait difficulties, and loss of coordination, as well as other bleeding and changes in platelet count or International Normalized Ratio (INR).(1) When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as confusion, headache, dizziness, nausea, visual changes, unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: In clinical studies, lecanemab was observed to increase ARIA-H, including microhemorrhage and intracerebral hemorrhage. Radiographic changes were classified as mild (<=4 new incidences), moderate (5 to 9 new incidences), or severe (10 or more new incidences. Patients were excluded from clinical trials if taking concurrent anticoagulants or anti-platelets.(1) In Studies 1 and 2, the maximum severity of ARIA-H microhemorrhage was mild in 9% (79/898), moderate in 2% (19/898), and severe in 3% (28/898) of patients. Intracerebral hemorrhage greater than 1 cm in diameter was reported in 0.7% (6/898) of patients in Study 2 after treatment with lecanemab compared to 0.1% (1/897) on placebo. Fatal events of intracerebral hemorrhage in patients taking lecanemab have been observed.(1) In Study 2, baseline use of antithrombotic medications (aspirin, other antiplatelets, or anticoagulants) were allowed if patient was on a stable dose. Aspirin was the most common antithrombotic agent. The incidence of ICH was 0.9% (3/328 patients) in patients taking lecanemab with a concomitant antithrombotic medication at the time of the event compared to 0.6% (3/545 patients) in those who did not receive an antithrombotic. Patients taking lecanemab with an anticoagulant alone or combined with an antiplatelet medication or aspirin had an incidence of intracerebral hemorrhage of 2.5% (2/79 patients) compared to none in patients who received placebo.
Anticoagulants; Antiplatelets; Thrombolytics/Caplacizumab
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Bleeding has been reported with the use of caplacizumab.(1)
CLINICAL EFFECTS: Concurrent use of caplacizumab with anticoagulants, antiplatelets, or thrombolytics may increase the risk of hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. hemophilia, coagulation factor deficiencies). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Avoid the use of caplacizumab with anticoagulants, antiplatelets, and thrombolytics. Interrupt caplacizumab therapy if clinically significant bleeding occurs. Patients may require von Willebrand factor concentrate to rapidly correct hemostasis. If caplacizumab is restarted, closely monitor for signs of bleeding.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Bleeding has been reported with caplacizumab. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of patients. Overall, bleeding events occurred in approximately 58% of patients on caplacizumab versus 43% of patients on placebo.(1) In post-marketing reports, cases of life-threatening and fatal bleeding were reported with caplacizumab.(1)
Anticoagulants; Fibrinolytics/Aducanumab
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Microhemorrhage has been reported with the use of aducanumab. Radiographic changes on brain MRI have been noted as amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H) which included microhemorrhage.(1)
CLINICAL EFFECTS: Concurrent use of aducanumab with either anticoagulants or fibrinolytics may increase the risk of hemorrhage.(1-3)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Evaluate concurrent use of aducanumab with anticoagulants or fibrinolytics.(1-3) Patients receiving concurrent therapy with aducanumab and anticoagulants or fibrinolytics should be closely monitored for signs and symptoms of bleeding and changes in platelet count or International Normalized Ratio (INR).(1) Enhanced observation is recommended for the first 8 doses of aducanumab, particularly with dose titration. MRI should be considered if a patient develops clinical symptoms of microhemorrhage.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of microhemorrhage, including headache, nausea/vomiting, confusion, dizziness, visual disturbance, gait difficulties, and loss of coordination. General signs of blood loss include decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as confusion, headache, dizziness, nausea, visual changes, unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: In two phase 3 studies, aducanumab was observed to increase ARIA-H, including microhemorrhage. Radiographic changes were classified as mild (<=4 new incidences), moderate (5 to 9 new incidences), or severe (10 or more new incidences. Patients were excluded from clinical trials if taking concurrent anticoagulants or anti-platelets.(1) In Studies 1 and 2, ARIA was observed in 41% of patients treated with aducanumab with a planned dose of 10 mg/kg, compared to 10% of patients on placebo.(1)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Anticoagulant;Antiplatelet;Thrombolytic/Icosapent Ethyl
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: In vitro data suggests that fish oils can competitively inhibit cyclooxygenase which decreases synthesis of thromboxane A1 leading to a decrease in platelet aggregation.(1)
CLINICAL EFFECTS: Concurrent use of anticoagulant, antiplatelet, or thrombolytic agents increase bleeding risks.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: If concurrent therapy is deemed medically necessary, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Specific studies with icosapent ethyl and affects on bleeding risk have not been conducted. Concurrent use of anticoagulant, antiplatelet, or thrombolytic agents may increase bleeding risks by impairing platelet function and prolonging bleeding time.(1) Several case reports have shown increased bleeding time and an increased risk of adverse effects from concurrent therapy.(2,3,4) A randomized placebo controlled study of 40 people taking omega-3 fatty acids and oral anticoagulants showed a significant prolongation in bleeding time.(5)
Anticoagulants/Lifileucel
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Internal organ hemorrhage, including intraabdominal and intracranial hemorrhage, has been reported in the presence of persistent or repeated thrombocytopenia following treatment with lifileucel.(1)
CLINICAL EFFECTS: Concurrent use or recent therapy with lifileucel and an anticoagulant may increase the risk of life-threatening hemorrhage, including intraabdominal and intracranial hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia).
PATIENT MANAGEMENT: The US manufacturer states patients with persistent or repeated thrombocytopenia after receiving lifileucel should not use anticoagulants. If anticoagulation therapy is warranted, close monitoring of patients must take place.(1) The US manufacturer recommends withholding or discontinuing lifileucel if internal organ hemorrhage is indicated, or patient is ineligible for IL-2 (aldesleukin) infusion.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: In the open-label single-arm study of 156 adult patients, two cases of internal organ hemorrhage (abdominal hemorrhage and intracranial hemorrhage) leading to death were reported.(1) The incidence of grade 3 or 4 laboratory abnormalities occurring in melanoma patients following treatment with lifileucel included thrombocytopenia (78.2%), neutropenia (69.2%) and anemia (58.3%). Prolonged thrombocytopenia occurred in 30.1% of patients.(1)
Anticoagulants; Antiplatelets/Fruquintinib; Surufatinib
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Bleeding has been reported with the use of fruquintinib and surufatinib.(1,2)
CLINICAL EFFECTS: Concurrent use of fruquintinib or surufatinib with either anticoagulants or antiplatelets may increase the risk of hemorrhage.(1,2)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Patients receiving concurrent therapy with fruquintinib and anticoagulants and/or antiplatelets should be closely monitored for changes in platelet count or in International Normalized Ratio (INR). If a serious bleeding event occurs, the manufacturer recommends permanent discontinuation of fruquintinib.(1) Patients receiving concurrent therapy with surufatinib and anticoagulants and/or antiplatelets should be closely monitored for changes in platelet count or in INR.If a serious bleeding event occurs, the manufacturer recommends permanent discontinuation of surufatinib.(2) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Bleeding has been reported with fruquintinib in three randomized, double-blinded, placebo-controlled clinical trials. The incidence of grade 1 and grade 2 bleeding events was 28.2%, including gastrointestinal bleeding (10.9%), hematuria (10.6%), and epistaxis (7.5%). The incidence of grade 3 or higher bleeding events was 2.1% and included gastrointestinal bleeding (1.6%) and hemoptysis (0.5%).(1) Bleeding has been reported with surufatinib in clinical trials. Grade 1 and 2 bleeding events included gastrointestinal bleeding, blood in the urine, and gum bleeding. The incidence of grade 3 or greater bleeding events was 4.5%, including gastrointestinal hemorrhage (1.9%), and cerebral hemorrhage (1.1%). Fatalities due to bleeding were reported in 0.3% of patients. The incidence of permanent discontinuation due to bleeding was 2.6% and the incidence of suspension of surufatinib due to bleeding was 3.8%.(2)
Anticoagulants; Antiplatelets/Obinutuzumab
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Severe and life-threatening thrombocytopenia has been reported during obinutuzumab therapy.(1) Anticoagulants and antiplatelets may have an additive risk of bleeding.
CLINICAL EFFECTS: Concurrent use of obinutuzumab with anticoagulants or antiplatelet agents may result in additive or synergistic effects, including fatal and non-fatal hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Monitor all patients frequently for thrombocytopenia and signs of bleeding. Consider withholding concomitant anticoagulants and antiplatelets, especially during the first cycle of obinutuzumab.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.
DISCUSSION: Obinutuzumab with chemotherapy has been reported to cause severe and life-threatening thrombocytopenia. Fatal hemorrhagic events have occurred in patients with NHL and CLL during obinutuzumab therapy, including during Cycle 1.(1)
Anticoagulants; Antiplatelets/Plasminogen
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Bleeding has been reported with the use of plasminogen.(1)
CLINICAL EFFECTS: Concurrent use of plasminogen with either anticoagulants or antiplatelets may increase the risk of active bleeding during plasminogen therapy, including bleeding from mucosal disease-related lesions that may manifest as gastrointestinal (GI) bleeding, hemoptysis, epistaxis, vaginal bleeding, or hematuria.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Patients receiving concurrent therapy with plasminogen and anticoagulants and/or antiplatelets should be closely monitored during plasminogen therapy for active bleeding from mucosal disease-related lesions, including GI bleeding, hemoptysis, epistaxis, vaginal bleeding, or hematuria.(1) Prior to initiation of treatment with plasminogen, confirm healing of lesions or wounds suspected as a source of a recent bleeding event. Monitor patients during and for 4 hours after infusion when administering plasminogen with concurrent anticoagulants, antiplatelet drugs, or other agents which may interfere with normal coagulation.(1) If patient experiences uncontrolled bleeding (defined as any gastrointestinal bleeding or bleeding from any other site that persists longer than 30 minutes), seek emergency care and discontinue plasminogen immediately.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Plasminogen has not been studied in patients at an increased risk of bleeding. Bleeding has been reported with plasminogen in a two single-arm, open-label clinical trials as well as in compassionate use programs. The incidence of hemorrhage in patients with Plasminogen Deficiency Type 1 was 16% (3/19 patients).(1) One of the bleeding events occurred two days after receiving the second dose of plasminogen in a patient with a recent history of GI bleeding due to gastric ulcers. The patient received plasminogen through a compassionate use program and the dose was 6.6 mg/kg body weight every 2 days. Endoscopy showed multiple ulcers with one actively bleeding ulcer near the pylorus.(1)
Anticoagulants; Antiplatelets/Tisotumab
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Bleeding, including hemorrhage, has been reported with the use of tisotumab.(1)
CLINICAL EFFECTS: Concurrent use of tisotumab with either anticoagulants, antiplatelets, or NSAIDs may increase the risk of hemorrhage.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: Patients receiving concurrent therapy with tisotumab and anticoagulants, antiplatelets, and/or NSAIDs should be closely monitored for signs and symptoms of bleeding and changes in platelet count or International Normalized Ratio (INR). For patients experiencing pulmonary or central nervous system (CNS) hemorrhage, permanently discontinue tisotumab. For grade 2 or greater hemorrhage in any other location, withhold until bleeding has resolved, blood hemoglobin is stable, there is no bleeding diathesis that could increase the risk of continuing therapy, and there is no anatomical or pathologic condition that can increase the risk of hemorrhage. After resolution, either resume treatment or permanently discontinue tisotumab.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Hemorrhage occurred in 62% of patients with cervical cancer treated with tisotumab across clinical trials. The most common all grade hemorrhage adverse reactions were epistaxis (44%), hematuria (10%), and vaginal hemorrhage (10%). Grade 3 hemorrhage occurred in 5% of patients.(1)
Anticoagulants; Thrombolytics/Remibrutinib
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Remibrutinib may cause bleeding. Anticoagulants and thrombolytics also affect hemostasis.(1)
CLINICAL EFFECTS: Concurrent use of remibrutinib with anticoagulants or thrombolytics may increase the risk of bleeding.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Consider the risks and benefits of concomitant administration of antithrombotic agents with remibrutinib. Interrupt treatment with remibrutinib if bleeding is observed and resume if the benefit is expected to outweigh the risk. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. Interrupt treatment with remibrutinib for 3 to 7 days pre- and post-surgery or invasive procedures.(1)
DISCUSSION: No data are available on concomitant use of remibrutinib with anticoagulants. The concomitant use of remibrutinib and anticoagulants was not allowed in clinical studies. Use of the antiplatelet agents, acetyl salicylic acid at doses up to 100 mg daily or clopidogrel up to 75 mg daily, was allowed in the remibrutinib clinical studies.(1)
Selected Anticoagulants; Antiplatelets/Ibrutinib
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Ibrutinib administration lowers platelet count in the majority of patients.(1,2) In addition, ibrutinib has been shown to inhibit collagen-mediated platelet aggregation.(3-4) Bleeding has been reported with the use of ibrutinib,(1-4) anticoagulants, or antiplatelets alone.
CLINICAL EFFECTS: Concurrent use of ibrutinib with either anticoagulants or antiplatelets may increase the risk of hemorrhage.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The Canadian product monograph for ibrutinib recommends concurrent use with anticoagulants or antiplatelets should be approached with caution. If therapeutic anticoagulation is required, consider temporarily withholding ibrutinib therapy until stable anticoagulation in achieved.(2) The US prescribing information for ibrutinib states patients receiving concurrent therapy with ibrutinib and anticoagulants and/or antiplatelets should be closely monitored for changes in platelet count or in International Normalized Ratio (INR). Carefully weigh the risks vs. benefits of concurrent therapy in patients with significant thrombocytopenia. If a bleeding event occurs, follow manufacturer instructions for ibrutinib dose adjustment.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Bleeding has been reported with ibrutinib alone.(1-3) Across 27 clinical trials, grade 3 or higher bleeding events, e.g. subdural hematoma, gastrointestinal bleeding or hematuria, have occurred in up to 4% of patients, with 0.4% fatality. Grade 3 or 4 thrombocytopenia occurred in 5-19% of patients. Bleeding events of any grade occurred in 39% of patients treated with ibrutinib.(1) Concurrent use of anticoagulants or antiplatelets has been reported to increase the risk for major bleeding. In clinical trials, major bleeding occurred in 3.1% of patients taking ibrutinib without concurrent anticoagulants or antiplatelets, 4.4% of patients on concurrent antiplatelets with or without anticoagulants, and 6.1% of patients on concurrent anticoagulants with or without antiplatelets.(1) In an open-label, phase 2 trial of patients with relapsed/refractory mantle cell lymphoma on ibrutinib, 61 patients (55%) on concurrent anticoagulants or antiplatelets had a higher rate of bleeding (69% any grade, 8% grade 3-4) than patients not on anticoagulants or antiplatelets (28% any grade, 4% grade 3-4).(5) A retrospective trial found a hazard ratio of 20 (95% CI, 2.1-200) for patients on ibrutinib with concurrent anticoagulants and antiplatelets. There was a trend towards an increased bleeding risk in patients on either anticoagulants or antiplatelets, but this was not statistically significant on multivariate analysis.(6) A case report of 2 patients with chronic lymphocytic leukemia (CLL) on ibrutinib and dabigatran demonstrated no stroke nor bleeding events during the mean 11.5 month follow-up.(7) A case report of 4 patients with lymphoproliferative disease on concurrent dabigatran and ibrutinib demonstrated no stroke nor major bleeding events. 1 patient experienced grade 2 conjunctival hemorrhage whilst on both ibrutinib and dabigatran. The anticoagulant was withheld and successfully re-initiated at a lower dose with no further bleeding events.(8)
Contraindications
*Active major bleeding.
*Known hypersensitivity to bivalirudin or any ingredient in the formulation.
- Cerebral amyloid angiopathy
- Deep peripheral nerve block
- Deep plexus block
- Hemorrhage
- Increased risk of bleeding
- Intracerebral hemorrhage
- Invasive procedure on spine
- Neuraxial anesthesia
- Placement of indwelling epidural catheter
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Kidney disease with likely reduction in glomerular filtration rate (GFr)
Adverse reactions
The most common adverse effect of bivalirudin is bleeding. Major bleeding occurred in 3.7% of patients in the BAT trials, and included intracranial bleeding, retroperitoneal bleeding, overt bleeding with a reduction in hemoglobin concentration of more than 3 g/dL, and blood transfusions of more than 2 units of blood.
More Frequent
- Hemorrhage
- Hypotension
Less Frequent
- Bradycardia
- Hypertension
Rare or Very Rare
- Anaphylaxis
- Bacterial sepsis
- Cerebral ischemia
- Fever
- Hypersensitivity drug reaction
- Infection
- Intracranial bleeding
- Pericardial tamponade
- Pulmonary edema
- Pulmonary hemorrhage
- Retroperitoneal hemorrhage
- Thrombotic disorder
- Ventricular fibrillation
More Frequent
- Back pain
- Dyspepsia
- Headache disorder
- Injection site sequelae
- Pain
- Pelvic pain
- Urinary retention
- Vomiting
Less Frequent
- Acute abdominal pain
- Insomnia
- Nausea
- Nervousness
- Symptoms of anxiety
Rare or Very Rare
- Acute cognitive impairment
Precautions
No enhanced messaging available.
Safety and efficacy of bivalirudin have not been established in pediatric patients.
There are no adequate and well-controlled studies of bivalirudin in pregnant women; bivalirudin has not been studied in the perinatal period due to risk of hemorrhage during delivery. Animal findings do not suggest fetal harm at exposure levels equivalent to 1.6 and 3.2 times the maximum human dose; however, at exposure levels equivalent to 5.4 times the maximum human dose, some skeletal abnormalities and a reduction in live births were observed, possibly due to maternal toxicity.
It is not known whether bivalirudin is distributed into milk; effects of the drug on milk production and the breast-fed infant have not been studied.
Administration of bivalirudin to lactating rats was not associated with developmental harm to the pups. The benefits of breast-feeding should be considered along with the importance of the drug to the woman and any potential adverse effects on the breast-fed child from the drug or underlying maternal condition.
The manufacturers make no specific dosage recommendations for geriatric patients.
In clinical trials of bivalirudin, geriatric patients experienced more bleeding complications than younger adults.
ICD codes
| Code | Type | Description |
|---|---|---|
| Percutaneous coronary intervention adjunct for thrombosis prevention | ||
| 0270346 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027034Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous approach |
| 0270356 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027035Z | ICD10PCS | Dilation of coronary artery, one artery with two drug-eluting intraluminal devices, percutaneous approach |
| 0270366 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027036Z | ICD10PCS | Dilation of coronary artery, one artery with three drug-eluting intraluminal devices, percutaneous approach |
| 0270376 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027037Z | ICD10PCS | Dilation of coronary artery, one artery with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02703D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous approach |
| 02703DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous approach |
| 02703E6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two intraluminal devices, percutaneous approach |
| 02703EZ | ICD10PCS | Dilation of coronary artery, one artery with two intraluminal devices, percutaneous approach |
| 02703F6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three intraluminal devices, percutaneous approach |
| 02703FZ | ICD10PCS | Dilation of coronary artery, one artery with three intraluminal devices, percutaneous approach |
| 02703G6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02703GZ | ICD10PCS | Dilation of coronary artery, one artery with four or more intraluminal devices, percutaneous approach |
| 02703T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02703TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous approach |
| 02703Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous approach |
| 02703ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous approach |
| 0270446 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027044Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0270456 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027045Z | ICD10PCS | Dilation of coronary artery, one artery with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0270466 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027046Z | ICD10PCS | Dilation of coronary artery, one artery with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0270476 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027047Z | ICD10PCS | Dilation of coronary artery, one artery with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02704D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02704DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous endoscopic approach |
| 02704E6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02704EZ | ICD10PCS | Dilation of coronary artery, one artery with two intraluminal devices, percutaneous endoscopic approach |
| 02704F6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02704FZ | ICD10PCS | Dilation of coronary artery, one artery with three intraluminal devices, percutaneous endoscopic approach |
| 02704G6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02704GZ | ICD10PCS | Dilation of coronary artery, one artery with four or more intraluminal devices, percutaneous endoscopic approach |
| 02704T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous endoscopic approach |
| 02704ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous endoscopic approach |
| 0271346 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027134Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous approach |
| 0271356 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027135Z | ICD10PCS | Dilation of coronary artery, two arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0271366 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027136Z | ICD10PCS | Dilation of coronary artery, two arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0271376 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027137Z | ICD10PCS | Dilation of coronary artery, two arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02713D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02713DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous approach |
| 02713E6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02713EZ | ICD10PCS | Dilation of coronary artery, two arteries with two intraluminal devices, percutaneous approach |
| 02713F6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02713FZ | ICD10PCS | Dilation of coronary artery, two arteries with three intraluminal devices, percutaneous approach |
| 02713G6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02713GZ | ICD10PCS | Dilation of coronary artery, two arteries with four or more intraluminal devices, percutaneous approach |
| 02713T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02713TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous approach |
| 02713Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous approach |
| 02713ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous approach |
| 0271446 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027144Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0271456 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027145Z | ICD10PCS | Dilation of coronary artery, two arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0271466 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027146Z | ICD10PCS | Dilation of coronary artery, two arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0271476 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027147Z | ICD10PCS | Dilation of coronary artery, two arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02714D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02714DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous endoscopic approach |
| 02714E6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02714EZ | ICD10PCS | Dilation of coronary artery, two arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02714F6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02714FZ | ICD10PCS | Dilation of coronary artery, two arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02714G6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02714GZ | ICD10PCS | Dilation of coronary artery, two arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02714T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous endoscopic approach |
| 02714ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous endoscopic approach |
| 0272346 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027234Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous approach |
| 0272356 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027235Z | ICD10PCS | Dilation of coronary artery, three arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0272366 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027236Z | ICD10PCS | Dilation of coronary artery, three arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0272376 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027237Z | ICD10PCS | Dilation of coronary artery, three arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02723D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02723DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous approach |
| 02723E6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02723EZ | ICD10PCS | Dilation of coronary artery, three arteries with two intraluminal devices, percutaneous approach |
| 02723F6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02723FZ | ICD10PCS | Dilation of coronary artery, three arteries with three intraluminal devices, percutaneous approach |
| 02723G6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02723GZ | ICD10PCS | Dilation of coronary artery, three arteries with four or more intraluminal devices, percutaneous approach |
| 02723T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02723TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous approach |
| 02723Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous approach |
| 02723ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous approach |
| 0272446 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027244Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0272456 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027245Z | ICD10PCS | Dilation of coronary artery, three arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0272466 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027246Z | ICD10PCS | Dilation of coronary artery, three arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0272476 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027247Z | ICD10PCS | Dilation of coronary artery, three arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02724D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02724DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous endoscopic approach |
| 02724E6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02724EZ | ICD10PCS | Dilation of coronary artery, three arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02724F6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02724FZ | ICD10PCS | Dilation of coronary artery, three arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02724G6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02724GZ | ICD10PCS | Dilation of coronary artery, three arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02724T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous endoscopic approach |
| 02724ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous endoscopic approach |
| 0273346 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027334Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous approach |
| 0273356 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027335Z | ICD10PCS | Dilation of coronary artery, four or more arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0273366 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027336Z | ICD10PCS | Dilation of coronary artery, four or more arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0273376 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027337Z | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02733D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02733DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous approach |
| 02733E6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02733EZ | ICD10PCS | Dilation of coronary artery, four or more arteries with two intraluminal devices, percutaneous approach |
| 02733F6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02733FZ | ICD10PCS | Dilation of coronary artery, four or more arteries with three intraluminal devices, percutaneous approach |
| 02733G6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02733GZ | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more intraluminal devices, percutaneous approach |
| 02733T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02733TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous approach |
| 02733Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous approach |
| 02733ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous approach |
| 0273446 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027344Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0273456 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027345Z | ICD10PCS | Dilation of coronary artery, four or more arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0273466 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027346Z | ICD10PCS | Dilation of coronary artery, four or more arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0273476 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027347Z | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02734D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02734DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous endoscopic approach |
| 02734E6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02734EZ | ICD10PCS | Dilation of coronary artery, four or more arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02734F6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02734FZ | ICD10PCS | Dilation of coronary artery, four or more arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02734G6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02734GZ | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02734T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous endoscopic approach |
| 02734ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous endoscopic approach |
| Thrombosis prevention during percutaneous coronary intervention in heparin-induced thrombocytopenia | ||
| 0270346 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027034Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous approach |
| 02703D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous approach |
| 02703DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous approach |
| 02703T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02703TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous approach |
| 02703Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous approach |
| 02703ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous approach |
| 0270446 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027044Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 02704D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02704DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous endoscopic approach |
| 02704T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous endoscopic approach |
| 02704ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous endoscopic approach |
| 0271346 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027134Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous approach |
| 02713D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02713DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous approach |
| 02713T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02713TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous approach |
| 02713Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous approach |
| 02713ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous approach |
| 0271446 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027144Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 02714D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02714DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous endoscopic approach |
| 02714T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous endoscopic approach |
| 02714ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous endoscopic approach |
| 0272346 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027234Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous approach |
| 02723D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02723DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous approach |
| 02723T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02723TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous approach |
| 02723Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous approach |
| 02723ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous approach |
| 0272446 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027244Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 02724D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02724DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous endoscopic approach |
| 02724T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous endoscopic approach |
| 02724ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous endoscopic approach |
| 0273346 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027334Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous approach |
| 02733D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02733DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous approach |
| 02733T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02733TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous approach |
| 02733Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous approach |
| 02733ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous approach |
| 0273446 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027344Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 02734D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02734DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous endoscopic approach |
| 02734T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous endoscopic approach |
| 02734ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous endoscopic approach |
| D75.82 | ICD10CM | Heparin induced thrombocytopenia (HIt) |
| Thrombosis with heparin-induced thrombocytopenia during percutaneous coronary intervention | ||
| 0270346 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027034Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous approach |
| 0270356 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027035Z | ICD10PCS | Dilation of coronary artery, one artery with two drug-eluting intraluminal devices, percutaneous approach |
| 0270366 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027036Z | ICD10PCS | Dilation of coronary artery, one artery with three drug-eluting intraluminal devices, percutaneous approach |
| 0270376 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027037Z | ICD10PCS | Dilation of coronary artery, one artery with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02703D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous approach |
| 02703DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous approach |
| 02703E6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two intraluminal devices, percutaneous approach |
| 02703EZ | ICD10PCS | Dilation of coronary artery, one artery with two intraluminal devices, percutaneous approach |
| 02703F6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three intraluminal devices, percutaneous approach |
| 02703FZ | ICD10PCS | Dilation of coronary artery, one artery with three intraluminal devices, percutaneous approach |
| 02703G6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02703GZ | ICD10PCS | Dilation of coronary artery, one artery with four or more intraluminal devices, percutaneous approach |
| 02703T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02703TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous approach |
| 02703Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous approach |
| 02703ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous approach |
| 0270446 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027044Z | ICD10PCS | Dilation of coronary artery, one artery with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0270456 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027045Z | ICD10PCS | Dilation of coronary artery, one artery with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0270466 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027046Z | ICD10PCS | Dilation of coronary artery, one artery with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0270476 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027047Z | ICD10PCS | Dilation of coronary artery, one artery with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02704D6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02704DZ | ICD10PCS | Dilation of coronary artery, one artery with intraluminal device, percutaneous endoscopic approach |
| 02704E6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02704EZ | ICD10PCS | Dilation of coronary artery, one artery with two intraluminal devices, percutaneous endoscopic approach |
| 02704F6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02704FZ | ICD10PCS | Dilation of coronary artery, one artery with three intraluminal devices, percutaneous endoscopic approach |
| 02704G6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02704GZ | ICD10PCS | Dilation of coronary artery, one artery with four or more intraluminal devices, percutaneous endoscopic approach |
| 02704T6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704TZ | ICD10PCS | Dilation of coronary artery, one artery with radioactive intraluminal device, percutaneous endoscopic approach |
| 02704Z6 | ICD10PCS | Dilation of coronary artery, one artery, bifurcation, percutaneous endoscopic approach |
| 02704ZZ | ICD10PCS | Dilation of coronary artery, one artery, percutaneous endoscopic approach |
| 0271346 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027134Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous approach |
| 0271356 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027135Z | ICD10PCS | Dilation of coronary artery, two arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0271366 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027136Z | ICD10PCS | Dilation of coronary artery, two arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0271376 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027137Z | ICD10PCS | Dilation of coronary artery, two arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02713D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02713DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous approach |
| 02713E6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02713EZ | ICD10PCS | Dilation of coronary artery, two arteries with two intraluminal devices, percutaneous approach |
| 02713F6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02713FZ | ICD10PCS | Dilation of coronary artery, two arteries with three intraluminal devices, percutaneous approach |
| 02713G6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02713GZ | ICD10PCS | Dilation of coronary artery, two arteries with four or more intraluminal devices, percutaneous approach |
| 02713T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02713TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous approach |
| 02713Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous approach |
| 02713ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous approach |
| 0271446 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027144Z | ICD10PCS | Dilation of coronary artery, two arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0271456 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027145Z | ICD10PCS | Dilation of coronary artery, two arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0271466 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027146Z | ICD10PCS | Dilation of coronary artery, two arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0271476 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027147Z | ICD10PCS | Dilation of coronary artery, two arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02714D6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02714DZ | ICD10PCS | Dilation of coronary artery, two arteries with intraluminal device, percutaneous endoscopic approach |
| 02714E6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02714EZ | ICD10PCS | Dilation of coronary artery, two arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02714F6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02714FZ | ICD10PCS | Dilation of coronary artery, two arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02714G6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02714GZ | ICD10PCS | Dilation of coronary artery, two arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02714T6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714TZ | ICD10PCS | Dilation of coronary artery, two arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02714Z6 | ICD10PCS | Dilation of coronary artery, two arteries, bifurcation, percutaneous endoscopic approach |
| 02714ZZ | ICD10PCS | Dilation of coronary artery, two arteries, percutaneous endoscopic approach |
| 0272346 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027234Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous approach |
| 0272356 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027235Z | ICD10PCS | Dilation of coronary artery, three arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0272366 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027236Z | ICD10PCS | Dilation of coronary artery, three arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0272376 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027237Z | ICD10PCS | Dilation of coronary artery, three arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02723D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02723DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous approach |
| 02723E6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02723EZ | ICD10PCS | Dilation of coronary artery, three arteries with two intraluminal devices, percutaneous approach |
| 02723F6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02723FZ | ICD10PCS | Dilation of coronary artery, three arteries with three intraluminal devices, percutaneous approach |
| 02723G6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02723GZ | ICD10PCS | Dilation of coronary artery, three arteries with four or more intraluminal devices, percutaneous approach |
| 02723T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02723TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous approach |
| 02723Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous approach |
| 02723ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous approach |
| 0272446 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027244Z | ICD10PCS | Dilation of coronary artery, three arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0272456 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027245Z | ICD10PCS | Dilation of coronary artery, three arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0272466 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027246Z | ICD10PCS | Dilation of coronary artery, three arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0272476 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027247Z | ICD10PCS | Dilation of coronary artery, three arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02724D6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02724DZ | ICD10PCS | Dilation of coronary artery, three arteries with intraluminal device, percutaneous endoscopic approach |
| 02724E6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02724EZ | ICD10PCS | Dilation of coronary artery, three arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02724F6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02724FZ | ICD10PCS | Dilation of coronary artery, three arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02724G6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02724GZ | ICD10PCS | Dilation of coronary artery, three arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02724T6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724TZ | ICD10PCS | Dilation of coronary artery, three arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02724Z6 | ICD10PCS | Dilation of coronary artery, three arteries, bifurcation, percutaneous endoscopic approach |
| 02724ZZ | ICD10PCS | Dilation of coronary artery, three arteries, percutaneous endoscopic approach |
| 0273346 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous approach |
| 027334Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous approach |
| 0273356 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous approach |
| 027335Z | ICD10PCS | Dilation of coronary artery, four or more arteries with two drug-eluting intraluminal devices, percutaneous approach |
| 0273366 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous approach |
| 027336Z | ICD10PCS | Dilation of coronary artery, four or more arteries with three drug-eluting intraluminal devices, percutaneous approach |
| 0273376 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous approach |
| 027337Z | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more drug-eluting intraluminal devices, percutaneous approach |
| 02733D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous approach |
| 02733DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous approach |
| 02733E6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two intraluminal devices, percutaneous approach |
| 02733EZ | ICD10PCS | Dilation of coronary artery, four or more arteries with two intraluminal devices, percutaneous approach |
| 02733F6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three intraluminal devices, percutaneous approach |
| 02733FZ | ICD10PCS | Dilation of coronary artery, four or more arteries with three intraluminal devices, percutaneous approach |
| 02733G6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more intraluminal devices, percutaneous approach |
| 02733GZ | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more intraluminal devices, percutaneous approach |
| 02733T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous approach |
| 02733TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous approach |
| 02733Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous approach |
| 02733ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous approach |
| 0273446 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 027344Z | ICD10PCS | Dilation of coronary artery, four or more arteries with drug-eluting intraluminal device, percutaneous endoscopic approach |
| 0273456 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027345Z | ICD10PCS | Dilation of coronary artery, four or more arteries with two drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0273466 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027346Z | ICD10PCS | Dilation of coronary artery, four or more arteries with three drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 0273476 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 027347Z | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more drug-eluting intraluminal devices, percutaneous endoscopic approach |
| 02734D6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with intraluminal device, percutaneous endoscopic approach |
| 02734DZ | ICD10PCS | Dilation of coronary artery, four or more arteries with intraluminal device, percutaneous endoscopic approach |
| 02734E6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with two intraluminal devices, percutaneous endoscopic approach |
| 02734EZ | ICD10PCS | Dilation of coronary artery, four or more arteries with two intraluminal devices, percutaneous endoscopic approach |
| 02734F6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with three intraluminal devices, percutaneous endoscopic approach |
| 02734FZ | ICD10PCS | Dilation of coronary artery, four or more arteries with three intraluminal devices, percutaneous endoscopic approach |
| 02734G6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with four or more intraluminal devices, percutaneous endoscopic approach |
| 02734GZ | ICD10PCS | Dilation of coronary artery, four or more arteries with four or more intraluminal devices, percutaneous endoscopic approach |
| 02734T6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734TZ | ICD10PCS | Dilation of coronary artery, four or more arteries with radioactive intraluminal device, percutaneous endoscopic approach |
| 02734Z6 | ICD10PCS | Dilation of coronary artery, four or more arteries, bifurcation, percutaneous endoscopic approach |
| 02734ZZ | ICD10PCS | Dilation of coronary artery, four or more arteries, percutaneous endoscopic approach |
| D75.82 | ICD10CM | Heparin induced thrombocytopenia (HIt) |
| D75.821 | ICD10CM | Non-immune heparin-induced thrombocytopenia |
| D75.822 | ICD10CM | Immune-mediated heparin-induced thrombocytopenia |
| D75.828 | ICD10CM | Other heparin-induced thrombocytopenia syndrome |
| D75.829 | ICD10CM | Heparin-induced thrombocytopenia, unspecified |
| D75.84 | ICD10CM | Other platelet-activating anti-Pf4 disorders |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.